enGene Therapeutics Rebrands as Company Nears Commercialization

enGene Holdings ( (ENGN) ) has provided an update.

enGene Therapeutics Inc., a clinical-stage, non-viral genetic medicines company focused on high-need diseases such as non-muscle invasive bladder cancer, is advancing its lead gene therapy candidate detalimogene voraplasmid through the Phase 2 LEGEND trial across multiple high-risk NMIBC patient cohorts. The program has been granted RMAT and Fast Track designations and is included in the FDA’s CMC Development and Readiness Pilot, positioning the asset as a potential first-in-class option for BCG-unresponsive disease.

On April 6, 2026, the company filed to change its corporate name from enGene Holdings Inc. to enGene Therapeutics Inc., with the change becoming effective April 8, 2026, and announced the move in an April 7, 2026 press release. The rebranding, which leaves Nasdaq tickers ENGN and ENGNW and security-holder rights unchanged but updates CUSIP and ISIN identifiers, is intended to signal enGene’s transition toward a commercial-stage organization ahead of a planned 2026 BLA submission for detalimogene and a potential 2027 market entry, marking an inflection point for investors and other stakeholders as the pipeline nears commercialization.

The most recent analyst rating on (ENGN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.

Spark’s Take on ENGN Stock

According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.

The score is held down primarily by weak financial performance (no revenue, inconsistent profitability, and substantial ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD and very low RSI/stochastics). A low P/E and a relatively strong balance sheet provide partial support but do not offset the operating and cash-flow risks.

To see Spark’s full report on ENGN stock, click here.

More about enGene Holdings

enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines, with a focus on delivering gene therapies to mucosal tissues and other organs to address diseases with high clinical need. Its lead program, detalimogene voraplasmid, is an investigational gene therapy for high-risk non-muscle invasive bladder cancer, built on the firm’s proprietary Dually Derivatized Oligochitosan platform.

enGene is running the multi-cohort Phase 2 LEGEND trial of detalimogene in high-risk NMIBC, including a pivotal cohort in Bacillus Calmette-Guérin–unresponsive carcinoma in situ that is intended to support a future Biologics License Application. Detalimogene has received RMAT and Fast Track designations from the U.S. FDA and is part of the agency’s CMC Development and Readiness Pilot program, underscoring its potential to address a significant unmet medical need in bladder cancer.

Average Trading Volume: 428,795

Technical Sentiment Signal: Sell

Current Market Cap: $489.7M

For a thorough assessment of ENGN stock, go to TipRanks’ Stock Analysis page.